Company / Financials
ENDRA Life Sciences Inc. Financials
FY2017-FY2020 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableRevenue
$0
FY2020 · -100.0% YoY
Net Income
-$11.7M
FY2020 · -19.7% YoY
Profit Margin
-
FY2020 · net income / revenue
ROE
-163.5%
FY2020 · return on equity
Total Assets
$8.8M
FY2020
Total Debt
-
FY2020
Equity
$7.2M
FY2020
ROA
-133.8%
FY2020 · return on assets
Statement paths
Financial highlights
Key Data Points
- Altman Z-Score -7.14 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Metric history
Revenue HistoryTotal revenue from operations$0-100.0% YoYNet Income HistoryProfit after all expenses and taxes-$11.7M-19.7% YoYGross Profit HistoryRevenue minus cost of goods sold$0-100.0% YoYCost of Revenue HistoryDirect costs of producing goods and services sold$0Operating Income HistoryProfit from core business operations before interest and taxes-$11.5M-27.5% YoYSG&A Expense HistorySelling, general, and administrative expenses$5.0M+33.3% YoYR&D Expense HistoryResearch and development spending$5.9M+25.3% YoYInterest Expense HistoryCost of borrowing and debt obligations$1.5KIncome Tax HistoryTotal income tax expense$0EPS (Diluted) HistoryDiluted earnings per share including stock options and convertibles-$2.34-7.8% YoY